Surgery Partners, Inc. (NASDAQ:SGRY) Given Consensus Rating of “Moderate Buy” by Brokerages

Surgery Partners, Inc. (NASDAQ:SGRY) has received a consensus rating of “Moderate Buy” from the eight brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $43.63.

Several research firms have commented on SGRY. StockNews.com raised shares of Surgery Partners from a “sell” rating to a “hold” rating in a research report on Thursday, March 21st. Benchmark reissued a “buy” rating and set a $50.00 target price on shares of Surgery Partners in a research report on Wednesday. Citigroup lowered their target price on shares of Surgery Partners from $43.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $43.00 target price on shares of Surgery Partners in a research report on Wednesday, April 10th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $49.00 price target on shares of Surgery Partners in a research report on Thursday, February 29th.

Surgery Partners Price Performance

Shares of NASDAQ:SGRY opened at $25.00 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.57 and a debt-to-equity ratio of 0.89. The firm has a market cap of $3.18 billion, a price-to-earnings ratio of -250.00, a P/E/G ratio of 2.28 and a beta of 2.75. Surgery Partners has a 1 year low of $22.05 and a 1 year high of $45.79. The business has a fifty day simple moving average of $27.80 and a 200 day simple moving average of $29.72.

Surgery Partners (NASDAQ:SGRY) last posted its earnings results on Monday, February 26th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.37 by $0.07. The firm had revenue of $735.40 million for the quarter, compared to the consensus estimate of $741.93 million. Surgery Partners had a negative net margin of 0.43% and a positive return on equity of 3.65%. The business’s quarterly revenue was up 4.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.22 earnings per share. As a group, sell-side analysts predict that Surgery Partners will post 0.78 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jason Eric Evans sold 4,840 shares of Surgery Partners stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $29.71, for a total transaction of $143,796.40. Following the sale, the chief executive officer now directly owns 459,670 shares of the company’s stock, valued at $13,656,795.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Jason Eric Evans sold 4,840 shares of Surgery Partners stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $29.71, for a total transaction of $143,796.40. Following the sale, the chief executive officer now directly owns 459,670 shares of the company’s stock, valued at $13,656,795.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Bradley R. Owens sold 1,040 shares of Surgery Partners stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $35.22, for a total value of $36,628.80. Following the sale, the insider now directly owns 73,149 shares in the company, valued at $2,576,307.78. The disclosure for this sale can be found here. Insiders have sold a total of 14,831 shares of company stock valued at $482,609 over the last three months. 2.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its stake in Surgery Partners by 23.2% during the third quarter. Wellington Management Group LLP now owns 8,022,700 shares of the company’s stock worth $234,664,000 after purchasing an additional 1,511,396 shares during the period. Quantbot Technologies LP bought a new position in Surgery Partners during the third quarter worth about $1,168,000. Invesco Ltd. lifted its stake in Surgery Partners by 9.3% during the third quarter. Invesco Ltd. now owns 3,604,357 shares of the company’s stock worth $105,427,000 after purchasing an additional 305,216 shares during the period. Barclays PLC lifted its stake in Surgery Partners by 204.9% during the third quarter. Barclays PLC now owns 289,663 shares of the company’s stock worth $8,472,000 after purchasing an additional 194,658 shares during the period. Finally, American Century Companies Inc. lifted its stake in Surgery Partners by 5.7% during the third quarter. American Century Companies Inc. now owns 888,171 shares of the company’s stock worth $25,979,000 after purchasing an additional 47,935 shares during the period.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.